Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.85 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.85 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098546 | 0.88 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL28206539 | 0.88 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL6518180 | 0.87 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7069119 | 0.86 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL5563021 | 0.85 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3823431 | 0.84 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL6512906 | 0.84 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL14407557 | 0.84 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL6556059 | 0.84 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4957555 | 0.83 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | FINER JEFFREY T (US) | 2013-02-28 | — | — | US | disclosed |
| US-8008311-B2 | Methods and compostions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008311-B2 | Methods and compostions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100063073-A1 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20030166933-A1 | Process for the racemization of chiral quinazolinones | CYTOKINETICS, INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003043995-A1 | PROCESS FOR THE RACEMIZATION OF CHIRAL QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003039460-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6562831-B1 | Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases | CYTOKINETICS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6545004-B1 | Treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | CYTOKINETICS, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1296959-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166933-A1 | Process for the racemization of chiral quinazolinones | ADH5, ADH1A, ADH1C | PDE4A 1496/4885PDE4B 1756/4885PDE4C 1865/4885 |
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | KIF5B, KIF5C, KIF2C | PDE4A 1452/4885PDE4B 1703/4885PDE4C 1584/4885 |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | KIF5B, KIF2C, KIF5C | PDE4A 1358/4885PDE4B 1549/4885PDE4C 1165/4885 |
| US-20100063073-A1 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | KIF5B, KIF2C, KIF18B | PDE4A 1656/4885PDE4B 2031/4885PDE4C 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.